RAS AL-KHAIMAH, 10th October, 2016 (WAM) -- The UAE-based pharmaceutical manufacturer Julphar, Gulf Pharmaceutical Industries, has held a conference at the InterContinental Dubai Festival City to announce the launch of two medications prescribed for the management of Type 2 diabetes, Xelevia and Velmetia.

The launch is part of Julphars license, supply and co-marketing agreement signed in April 2014 with the global pharmaceutical leader, Merck Sharp & Dohme.

Speaking on the occasion, Dr. Hosam Badr, Marketing Director at Julphar, said, "The launch of Xelevia and Velmetia is part of our continuing mission to develop Julphar diabetes portfolio, to support healthcare community in the region."

Copyright Emirates News Agency (WAM) 2016.